文献速递神经肌肉病

夏科-马里-图思病的临床结局评估与生物标志物

Clinical Outcome Assessments and Biomarkers in Charcot-Marie-Tooth Disease.
PubMed 文献 · Neurology · 2024-11-25

早期临床量表存在局限,促使了心理测量学支持的新量表开发,但许多尚未在纵向研究中正式测试。下肢MRI肌肉脂肪分数是迄今反应性最好的生物标志物,血清生物标志物可区分患者与对照,但对有效治疗的反应性仍未知。

要点

  • 早期量表如神经病变损害评分、总体神经病变限制量表和CMT神经病变评分存在局限。
  • 新量表包括CMT神经病变评分第2版、CMT儿童量表、CMT婴儿量表、CMT功能结局测量和CMT健康指数。
  • 下肢MRI肌肉脂肪分数是迄今反应性最好的生物标志物,但其与功能结局的关系和治疗试验中的表现仍不确定。

核心结论

  • 尽管CMT最佳结局测量组合尚未确立,许多最有前景的COA和生物标志物正在进行的临床试验中接受检验。

主要发现

  • 自然史研究和已完成的临床试验凸显了早期临床量表(神经病变损害评分、总体神经病变限制量表、CMT神经病变评分)的局限性。
  • 这些研究促使了心理测量学支持的新量表开发,包括CMT神经病变评分第2版、CMT儿童量表、CMT婴儿量表、CMT功能结局测量和CMT健康指数。
  • 许多新量表尚未在纵向研究中正式测试。
  • 下肢MRI肌肉脂肪分数是迄今反应性最好的生物标志物,但其与功能结局的关系和治疗试验中的表现仍不确定。
  • 血清生物标志物包括神经丝轻链、跨膜蛋白酶丝氨酸5、特定微小RNA、神经细胞黏附分子1和生长分化因子15可可靠区分CMT患者与对照,但对有效治疗的反应性仍未知。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 许多新量表尚未在纵向研究中正式测试。
  • 下肢MRI肌肉脂肪分数与功能结局的关系及其在治疗试验中的表现仍不确定。
  • 血清生物标志物对有效治疗的反应性仍未知。
  • CMT最佳结局测量组合尚未确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Charcot-Marie-Tooth disease (CMT) encompasses a diverse group of genetic forms of inherited peripheral neuropathy and stands as the most common hereditary neurologic disease worldwide. At present, no disease-modifying treatments exist for any form of CMT. However, promising therapeutic strategies are rapidly emerging, necessitating careful consideration of clinical outcome assessments (COAs) and clinical trial design. In this review, we discuss the challenges and successes over the past 2 decades in efforts to design and validate COAs and disease biomarkers of CMT. Natural history studies and completed clinical trials have underscored the limitations of early clinical scales for CMT, including the neuropathy impairment score, overall neuropathy limitation scale, and CMT neuropathy score. These studies prompted the development of newer, psychometrically supported scales including the CMT neuropathy score version 2, CMT pediatric scale, CMT infant scale, CMT functional outcome measure, and CMT health index. Although promising, many of these scales have yet to be formally tested in longitudinal studies. Given inherent challenges of relying solely on COAs in slowly progressive forms of CMT, there is growing recognition of the need for objective disease biomarkers that could serve as surrogate end points in clinical trials. Among these, MRI muscle fat fraction in the lower extremities has proven the most responsive biomarker to date, although its relationship to functional outcomes and its performance in treatment trials remain uncertain. Serum biomarkers including neurofilament light, transmembrane protease serine 5, specific microRNAs, neural cell adhesion molecule 1, and growth and differentiation factor 15 reliably distinguish patients with CMT from controls, but their responsiveness to effective therapies also remains unknown. Although the optimal combination of outcome measures in CMT has yet to be established, many of the most promising COAs and biomarkers are now being put to the test in ongoing clinical trials. These early studies will also help address other critical clinical trial considerations, such as patient selection and enrollment targets, which will become increasingly important in this exciting new era of bringing the first disease-modifying treatments to people living with CMT.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. McCray BA, Fridman V. Clinical Outcome Assessments and Biomarkers in Charcot-Marie-Tooth Disease. Neurology. 2024. PMID: 39586049. doi:10.1212/WNL.0000000000210120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。